个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Zhou, C.[1] * ; Hu, M.[2] ; Zhu, X.[2] ; Sun, Y.[2] ; Lu, X.[3] ; Wang, J.[4] ; Wang, M.[5] ; Cheng, Y.[6] ; Chen, Y.[7] ; Zhao, Y.[8] ; Shi, Y.[9,10] ; Lu, Y.[11] ; Shi, M.[12] ; Zhang, H.[13] ; Huang, X.[14] ; Wang, Z.[3] ; Ding, Z.[2] ; Li, H.[4] ; Chen, G.[4] ; Wu, Y.[15,16] ;
单位： [1]Tongji Univ, Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China [2]Dizal Jiangsu Pharmaceut Co Ltd, Shanghai, Peoples R China [3]Astrazeneca, Res & Dev Informat, Shanghai, Peoples R China [4]Astrazeneca, China Dev Unit, Shanghai, Peoples R China [5]Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp Med, Beijing, Peoples R China [6]Canc Hosp Jilin Prov, Dept Oncol, Changchun, Jilin, Peoples R China [7]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Ctr, Wuhan, Hubei, Peoples R China [8]Henan Canc Hosp, Dept Pulm & Crit Care Med, Zhengzhou, Henan, Peoples R China [9]Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Clin Res Ctr Canc, Med Oncol,Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [10]Peking Union Med Coll, Beijing, Peoples R China [11]Sichuan Univ, West China Sch Clin Med, Dept Thorac Oncol, West China Hosp, Chengdu, Sichuan, Peoples R China [12]Jiangsu Canc Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China [13]Tangdu Hosp, Tangdu Comprehens Canc Ctr, Dept Oncol, Xian, Shaanxi, Peoples R China [14]Astrazeneca, Cambridge, England [15]Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China [16]Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
出处：
DOI： 10.1016/j.jtho.2018.08.293
ISSN：

关键词： non-small cell lung cancer osimertinib resistance mechanisms

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2016]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者：
第一作者单位： [1]Tongji Univ, Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou C.,Hu M.,Zhu X.,et al.Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial[J].JOURNAL OF THORACIC ONCOLOGY.2018,13(10):S345-S345.doi:10.1016/j.jtho.2018.08.293.
APA：
Zhou, C.,Hu, M.,Zhu, X.,Sun, Y.,Lu, X....&Wu, Y..(2018).Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial.JOURNAL OF THORACIC ONCOLOGY,13,(10)
MLA：
Zhou, C.,et al."Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial".JOURNAL OF THORACIC ONCOLOGY 13..10(2018):S345-S345

相关文献

[1]ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC) [2]Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) [3]A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer [4]Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3/SOCS3 and KEAP1/NRF2 pathways in non-small cell lung cancer [5]Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations [6]Progress of non-small-cell lung cancer with ROS1 rearrangement [7]AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS) [8]Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report [9]Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China [10]Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）